Recombinant mitotoxin basic fibroblast growth factor-saporin reduces venous anastomotic intimal hyperplasia in the arteriovenous graft

Circulation

Volumn 94, Issue 8, 1996, Pages 1989-1995

  Chen, Changyi ^a   Mattar, Samer G ^a   Hughes, John D ^a   Pierce, Glenn F ^b   Cook, Jennifer E ^b   Ku, David N ^a   Hanson, Stephen R ^a   Lumsden, Alan B ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Prizm Pharmaceuticals Inc   (United States)

^c Box M 11 ^*  (United States)

Author keywords

grafting; growth substances; hyperplasia; saporin

Indexed keywords

POLITEF; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; SAPORIN;

ANIMAL MODEL; ARTERY ANASTOMOSIS; ARTICLE; BLOOD VESSEL GRAFT; CELL PROLIFERATION; CONTROLLED STUDY; DOG; DRUG DELIVERY SYSTEM; DRUG INFUSION; GRAFT FAILURE; INTIMA; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; VEIN ANASTOMOSIS;

EID: 0029818354     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.8.1989     Document Type: Article

References (47)

1. Swedberg SH, Brown BG, Sigley R, Wight TN, Gordon D, Nicholls SC. Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients: clinical, immunocytochemical, light and electron microscopic assessment. Circulation. 1989;80: 1726-1736.
2. Tordoir JH, Herman JM, Kwan TS, Diderich PM. Long-term follow-up of the polytetrafluoroethylene (PTFE) prosthesis as an arteriovenous fistula for hemodialysis. Eur J Vasc Surg. 1988;2:3-7.
3. Zibari GB, Rohr MS, Landreneau MD, Bridges RM, DeVault GA, Petty FN, Costley KJ, Brown ST, McDonald JC. Complications from permanent hemodialysis vascular access. Surgery. 1988;104: 681-686.
4. Scottiurai VS. Biogenesis and etiology of distal anastomotic intimal hyperplasia. Int Angiol. 1990;9:59-69.
5. Connolly JE, Brownell DA, Levine EF, McCart PM. Complications of renal dialysis access procedures. Arch Surg. 1984;119:1325-1328.
6. Lindner V, Lappi DA, Baird A, Majack RA, Reidy MA. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res. 1991;68:106-113.
7. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci U S A. 1991;88:3739-3743.
8. Mignatti P, Rifkin DB. Release of basic fibroblast growth factor, an angiogenic factor devoid of secretory signal sequence: a trivial phenomenon or a novel secretion mechanism? J Cell Biochem. 1991; 47:201-207.
9. Casscells W, Lappi DA, Olwin BB, Wai C, Siegman M, Speir EH, Sasse J, Baird A. Elimination of smooth muscle cells in experimental restenosis: targeting of fibroblast growth factor receptors. Proc Natl Acad Sci U S A. 1992;89:7159-7163.
10. Brothers TE, Robison JG, Elliott BM, Boggs JM, Frankel AE, Willingham MC. Upregulation of b-FGF receptor expression after carotid bypass. J Surg Res. 1995;58:28-32.
11. Hawker JR, Granger H. Internalized bFGF is translocated to the nuclei of venular endothelial cells and established fibroblast cell lines. Ann N Y Acad Sci. 1991;638:424-426.
12. Cuevas P, Gonzalez AM, Carceller F, Baird A. Vascular response to basic fibroblast growth factor when infused onto the normal adven- titia or into the injured media of the rat carotid artery. Circ Res. 1991;69:360-369.
13. Stirpe F, Barbieri L. Ribosome-inactivating proteins up to date. FASEB Lett. 1986;195:1-8.
14. Siena S, Bregni M, Fotmosa A, Martineau D, Lappi DA, Bonadonna G, Gianni AM. Evaluation of antihuman T lymphocyte saporin immunotoxins potentially useful in human transplantation. Transplantation. 1988;46:747-753.
15. Siena S, Lappi DA, Bregni M, Formosa A. Villa S, Soria M, Bonadonna G, Gianni AM. Synthesis and characterization of an antihuman T-lymphocyte saporin immunotoxin (OKT1-SAP) with in vivo stability in nonhuman primates. Blood. 1988;72:756-760.
16. Bregni M, Lappi DA, Siena S, Formaso A, Soria M, Bonadonna G, Gianni AM. Activity of a monoclonal antibody-saporin-6 conjugate against B-lymphoma cells. J Natl Cancer Inst. 1988;80:511-517.
17. Bergamaschi G, Cazzola M, Dezza L, Savino E, Consonni L, Lappi DA. Killing of K562 cells with conjugates between human transferrin and a ribosome-inactivating protein (SO-6). Br J Haematol. 1988; 68:379-384.
18. Lappi DA, Martineau D, Baird A. Biological and chemical characterization of basic FGF-saporin mitotoxin. Biochem Biophys Res Commun. 1989;160:917-923.
19. Martineau D, Lappi DA, Amburn E, Baird A. Basic fibroblast growth factor-saporin mitotoxin: in vitro studies of its cell-killing activity and of substances that alter that activity. Ann N Y Acad Sci. 1991; 638:438-441.
20. Lappi DA, Maher PA, Martineau D, Baird A. The basic fibroblast growth factor-saporin mitotoxin acts through the basic fibroblast growth factor receptor. J Cell Physiol. 1991;147:17-26.
21. Scott NA, Nunes GL, King SB, Harker LA, Hanson SR. Local delivery of an antithrombin inhibits platelet-dependent thrombosis. Circulation. 1994;90:1951-1955.
22. Chen C, Hanson SR, Lumsden AB. Boundary layer infusion of heparin prevents thrombosis and reduces neointimal hyperplasia in venous PTFE grafts without systemic anticoagulation. J Vasc Surg. 1995;22:237-247.
23. Lappi DA, Ying W, Barthelemy I, Martneau D, Prieto I, Benatti L, Soria M, Baird A. Expression and activities of a recombinant basic fibroblast growth factor-saporin fusion protein. J Biol Chem. 1994; 17:12552-12558.
24. Chen C, Suwyn C, Mattar S, Coyle KA, Ku ND, Lumsden AB. Distribution of tenascin in human neointimal hyperplastic lesions. Surg Forum. 1994;45:382-385.
25. Kondo T, FitzGerald D, Chaudhary VK, Adhya S, Pastan I. Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain. J Biol Chem. 1988;263: 9470-9475.
26. FitzGerald D, Pastan I. Targeted toxin therapy for the treatment of cancer. J Natl Cancer Inst. 1989;81:1455-1463.
27. Epstein SE, Siegall CB, Biro S, Fu YM, FitzGerald D, Pastan I. Cytotoxic effects of a recombinant chimeric toxin on rapidly proliferating vascular smooth muscle cells. Circulation. 1991;84:778-787.
28. Biro S, Siegall CB, Fu YM, Speir E, Pastan I, Epstein SE. In vitro effects of a recombinant toxin targeted to the FGF receptor on rat vascular smooth muscle and endothelial cells. Circ Res. 1992;71: 640-645.
29. Miller DD, Paige SB, Tio FO, Bailey SR, Waters CA, Woodworth TG, Nichols JC. Lymphocyte/monocyte interleukin-2 receptor targeted fusion toxin therapy with DAB486-IL2 prevents proliferative post-angioplasty restenosis. Circulation. 1991;84(suppl II):II-70. Abstract.
30. Pickering JG, Bacha PA, Weir L, Jekanowski J, Nichols JC, Isner JM. Prevention of smooth muscle cell outgrowth from human atherosclerotic plaque by a recombinant cytotoxin specific for the epidermal growth factor receptor. J Clin Invest. 1993;91:724-729.
31. Powell JS, Clozel JP, Muller RKM, Kuhn H, Hebti F, Hosang M, Baumgartner HR. Inhibition of angiotensin-converting enzyme prevents myointimal proliferation after vascular injury. Science. 1989; 245:186-188.
32. Hanson SR, Powell JS, Dodson T, Lumsden AB, Kelly AB, Anderson JS, Clowes AW, Harker LA. Effects of angiotensin converting enzyme inhibition with cilazapril on intimal hyperplasia in injured arteries and vascular grafts in the baboon. Hypertension. 1991; 184(suppl I):I-1170-I-1182.
33. MERCATOR Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Circulation. 1992;86:100-110.
34. Landau C, Lange RA, Hillis LD. Percutaneous transluminal coronary angioplasty. N Engl J Med. 1994;330:981-993.
35. Ohno T, Gordon D, San H, Pompili VJ, Imperiale MJ, Nabel GJ, Nabel EG. Gene therapy for vascular smooth muscle cell proliferation after artery injury. Science. 1994;265:781-784.
36. Binns RL, Ku DN, Stewart MT, Ansley JP, Coyle KA. Optimal graft diameter: effect of wall shear stress on vascular healing. J Vasc Surg. 1989;10:326-337.
37. Chen C, Mattar SG, Allen AC, Nor B, Lumsden AB. Tenascin distribution and cell proliferation in the early stage of arteriovenous loop graft. J Am Soc Nephrol. 1994;5:411. Abstract.
38. Lumsden AB, Chen C, Ku DN. Neovascularization in the venous neointimal hyperplastic lesions of arteriovenous grafts. J Am Soc Nephrol. 1994;5:421. Abstract.
39. Lumsden AB, Chen C. Arteriovenous fistula for dialysis access: clinical use and pathophysiologic changes. In: Brockbank KGM, ed. Principles of Autologous, Allogenic, and Cryopreserved Venous Transplantation. Austin, Tex: RG Landes Co; 1995:135-144.
40. Chen C, Allen RC, Jaffe MB, Lumsden AB. Quantitative study of neointimal hyperplasia in a canine model of arteriovenous polytetrafluoroethylene grafts. Presented at the Fifth Annual Winter Meeting of the Peripheral Vascular Surgery Society; January 27-29, 1995; Breckenridge, Colo.
41. Nerem RM. Vibration induced shear stress: the relationship to Raynaud's phenomenon of occupational origin. Arch Environ Health. 1973;26:105-110.
42. Fillinger MF, Reinitz ER, Schwartz RA, Resetarits DE, Paskanik AM, Bredenbery CE. Beneficial effects of banding on venous intimal-medial hyperplasia in arteriovenous loop grafts. Am J Surg. 1989;158:87-94.
43. Fillinger MF, Reinitz ER, Schwartz RA, Resetarits DE, Paskanik AM, Bruch D, Bredenbery CE. Graft geometry and venous intimal-medial hyperplasia in arteriovenous loop grafts. J Vasc Surg. 1990; 11:556-566.
44. Lazarous DF, Scheinowitz M, Shou M, Hodge E, Rajanayagam S, Hunsberger S, Robison WG, Stiber JA, Correa R, Epstein SE, Unger EF. Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart. Circulation. 1995;91:145-153.
45. Gottstein C, Winkler U, Bohlen H, Diehl V, Engert A. Immunotoxins: is there a clinical value? Ann Oncol. 1994;5(suppl 1):S97-S103.
46. Morrison SL, Johson MJ, Herzenberg LA. Qi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A. 1984;81: 6851-6855.
47. Dhingra K, Fritsche H, Murray JL, LoBuglio AF, Khazaeli MB, Kelley S, Tepper M, Greene D, Booser D, Buzdar A. Suppression of human antimouse antibody response by deoxyspergualin (DSG): a phase I study. Adv Exp Med Biol. 1994;353:193-202.